cardin health maintain strong posit
updat forecast estim
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research
estim
price data
rate updat
currenc amount express
busi strategi outlook
methodolog valu compani
busi strategi outlook
believ cardin health play import role within
healthcar market result possess wide econom
moat drug distributor abl turn signific size
market share key competit advantag cardin
import cogs within pharmaceut industri mani
supply-chain particip depend servic streamlin
product distribut procur expect use
pharmaceut increas next sever year
provid solid platform cardin continu success
cardin third-largest pharmaceut distributor revenu
main supplier retail pharmaci network
firm also suppli sever larg provid gpo mass
retail razor-thin profit contract
enorm amount capit need build top-tier global drug
wholesaling/distribut oper
competit foundat cardin larg kept new
entrant bay
cardin also made strateg move believ
benefici long term one partner
caremark jointli sourc gener drug product
allow opportun off-set current profit issu
drive econom valu long-term combin sourc entiti
abl garner top-tier price discount gener
howev enthusiast cardin recent push
medic equip manufactur distribut
initi believ would case oper
provid signific headwind price manufactur
issu recent formul although healthcar spend
growth continu exceed growth case
low-tech medic surgic product gener
experi market growth low singl digit believ
asset could suppress roic detract valu firm
top-tier core drug distribut oper accordingli
pleas new manag team taken step
restructur non-core busi
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
cardin health major distributor pharmaceut medic
suppli pharmaci hospit also major logist partner
mani brand manufactur provid market forecast product
product inventori effici distribut servic player
largest retail pharmaci custom retail pharmaci
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
firm
result
fair valu estim cardin struggl
within medic suppli busi weigh
companywid restructur plan refocu effort back
toward optim core drug distribut oper
model revenu profit growth forecast
firm medic suppli segment histor level
believ firm seek retrench oper
also factor rel high tax rate
next year captur tax issu firm face certain
region abl total off-set loss
cordi unit addit factor restructur
charg next two year manag
implement busi realign plan refocu
firm oper gener econom profit
also account firm gener sourc partnership
believ add materi bottom
line along acquisit harvard drug believ
two oper tactic yield excel roic
next sever year offset posit action
firm recent medic devic manufactur busi
believ provid lacklust capit return
medic product manufactur distribut fall outsid
cardin core drug distribut oper
drag core compet
boost posit firm-specif outlook posit
age popul influx previous
uninsur peopl healthcar market greater
use pharmaceut front-lin treatment provid
platform solid top- bottom-lin growth
accordingli factor five-year revenu
compound-annual-growth-rate averag oper margin explicit
potenti price headwind supplier price pressur
pharmaceut market growth effect redoak
sourc jv ultim outcom
restructur medic suppli segment bull-cas
scenario factor less price profit
pressur also assum cardin abl exert even
negoti leverag given gener sourc
partnership also assum medic suppli
busi recov expect along drug
spend growth enhanc return addit factor
high-single-digit drug industri growth uptak
drug usag increas faster initi expect
scenario fair valu estim increas
bear case assum effort bring regulatori
price pressur industri succeed addit
assum gener sourc partnership
advantag firm medic suppli segment
continu value-destruct also assum secular
industri growth driver fail materi par current
expect scenario fair valu estim
decreas
believ three major pharmaceut wholesal
possess wide econom moat turn
coloss size key competit advantag
retail outlet solidifi long-term competit
posit accord center medicar
medicaid servic estim total amount retail
pharmaceut spend unit state close
billion major spend flow
oper
distributor domin drive robust sustain
econom profit player
major
scenario analysi take consider effect
estim
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
led outsiz roic trend believ last
believ cardin stabl econom moat trend even
though firm face near-term issu long-term
trend highli favor demograph trend
expans government-sponsor healthcar coverag
bolster secular environ perspect
drug distributor abl
pharmaceut spend next sever decad
critic role pharmaceut industri main
sourc drug suppli signific portion retail
pharmaci outlet effici distributor drug
combin market share well
combin dynam slim industri profit keep new
entrant bay new player would tough time
carv enough share effici leverag
posit econom profit
addit plethora regulatori complianc
industri relationship requir viabl drug
wholesal add stalwart barrier entri
variabl solidifi long-term wide econom moat
major three drug distributor firm also abl
obtain signific price discount drug manufactur
mani custom acquir
make essenti cogs pharmaceut industri
allow build excel asset effici effect rout
infrastructur
unparallel logist expertis driven decent asset
return howev abil effect manag
capit base true driver outsiz return cardin
firm abl produc top-tier asset turn cash
convers inventori manag metric
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
ocardin one three major pharmaceut
wholesal close billion
advantag drug manufactur
revenu size posit
opharmaceut spend grow solid clip
next decad given demograph shift
expans medic coverag government-
specialti drug spend continu increas
believ distributor opportun captur
valu nich market increas bottom
oprofit margin cardin razor-thin make
effort procur cheaper suppli gener
product cardin partner
enhanc negoti power fixed-cost scale
partnership fail outlook futur revenu
profit growth take hit
ohistor cardin acquir non-core busi
order drive growth strategi creat
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
equival begin period
total avail debt servic
oblig commit
total oblig commit
adjust free
gener
gener revolv adjust
commit
cardin rel solid financi health firm
cash flow healthcare-rel oper provid
solid foundat long-term financi stabil capit
leverag increas materi fund two
third billion acquisit patient
recoveri busi debt howev firm strong
cash gener allow easili pay debt
oblig expect see cardin current debt/equ
ratio fall next sever year reach
end five-year explicit forecast period
cardin face three main risk push stricter
regul pharmaceut industri player increas
price pressur payer expans outsid
core drug wholes activ concert
effort certain healthcar market stakehold
feder govern enact price control drug
sold distributor acquisit cost becom
greater result could hurt cardin return
addit payer sought curb growth drug
spend last year believ trend
remain place sever year manufactur
retail pharmaci custom unwil budg
current price demand cardin profit could
squeez final cardin move drive growth
expand non-core busi
medic device/consumable-product manufactur
distribut believ market lucr
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
longtim cardin employe mike kaufmann took
ceo januari replac georg barrett
serv head posit sinc move
slightli surpris come shock given
recent struggl cardin barrett almost decad
set overal strategi drug wholesal
kaufmann held sever role firm
tenur becom ceo cardin
cfo led mani firm major divis
believ deep knowledg everi aspect cardin
serv well overal chief
repres date owner name posit common share held report holder issuer
fidel manag research compani
share
fund
share
fund
compani exit
histor standpoint question
capit alloc decis previou manag
team particular concern
cardin expans intern medic
chines
pharmaceut market major issu cordi
segment valid concern believ
materi level sharehold valu destroy
result misstep howev also believ
firm oper execut capit manag
core pharmaceut distribut segment highli
benefici sharehold blend two area
combin recent appoint new ceo
rate firm stewardship standard would
consid stewardship downgrad signific capit
core
pharmaceut divis new ceo
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
cardin report mix quarter posit long-term
cardin report mix quarter revenu grew
robust clip profit continu pressur
environ believ need sourc deliv
drug cost effect effici manner remain
posit fundament drug distributor dynam
form strong foundat cardin
competit posit view core drug
wholes oper need drug
manufactur retail pharmaci matter
market dynam shift accordingli reiter
wide-moat rate fair valu estim
cardin manag reiter guidanc year
confid expect incorpor conserv
outlook find encourag develop
point continu stabil oper gener
deflat moder brand inflat remain
expect trajectori manag state guidanc
incorpor scenario brand inflat could fall
basi point current expect
howev team state feel highli confid
inflat expect given convers
firm also reorgan oper manag
state everyth tabl part
reorgan includ firm refocus much
manageri bandwidth asset
build effici stabil core
pharmaceut wholesal segment major chang
firm previou strategi expand busi
portfolio global reach applaud new
manag team strategi model
modest profit improv segment forecast
oper margin expand basi point
end explicit forecast period believ
reflect conserv outlook incorpor greater
infrastructur effici modest price spread less
variabl tie brand price
ceo mike kaufman state earn call
process revamp firm busi refocus
effort process improv continu well
fiscal year believ strategi posit
long-term given greater focu optim drug
wholes oper expand
specialti
pharmaceut oper perspect
effort ultim build signific sharehold valu
beyond fiscal cardin posit critic cogs
within global pharmaceut suppli chain
dynam provid opportun produc signific
econom profit long-term thu current
discount firm stock price present opportun
investor long-term time horizon wide moat
busi signific discount
cardin report decent continu realign
even though may materi chang
next sever year variou part
pharmaceut market oper need sourc
deliv drug cost-effect effici manner
chang believ fundament factor form
strong foundat cardin
core drug
wholes oper need drug
manufactur retail pharmaci matter
market dynam shift thu reiter wide
moat rate fair valu estim drug
cardin report stabil oper
gener deflat continu moder firm
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
reorgan oper part reorgan
includ firm refocus much manageri
bandwidth asset invest toward build
effici stabil core pharmaceut
wholesal segment major chang firm
previou strategi expand busi portfolio
global reach applaud new manag team
strategi model modest profit
improv segment model oper
margin expand fiscal fiscal
basi point believ reflect
conserv outlook incorpor greater infrastructur
effici modest price spread less variabl tie
brand price
oper refocus effort process improv
continu fiscal believ strategi
posit long-term near-term
headwind firm current face eventu abat
believ greater focu optim drug
wholes oper expans specialti
pharmaceut oper bolster cardin result
sharehold valu beyond fiscal cardin
posit critic cogs within global pharmaceut
suppli chain dynam provid opportun
produc signific econom profit long-term
thu current discount firm stock price present
opportun investor long-term time horizon
wide-moat busi signific discount
remain unenthusiast cardin push
medic equip manufacturing/distribut believ
previou manag team effort expand
busi strateg misstep although global
healthcar spend remain robust
forese futur case low-tech
medic surgic product gener
commod main focu segment near-
term improv cordi busi line
necessarili among top-tier within categori
believ cardin reset price product
order clear current inventori backlog -- pressur
profit fear dynam would eventu
develop cardin long neg toward
previou capit alloc polici non-drug
wholes acquisit perspect best
cours manag may pursu altern
strategi asset divest much
medic suppli oper share much synergi
wide-moat drug distribut oper
cardin fairli new ceo mike kaufman state
earn call process reevalu firm
despit amazon acquisit pillpack market
june amazon announc purchas mail-ord
pharmaci start-up pillpack move give amazon
foothold within pharmaceut suppli chain
logic step on-line conglomer make
believ retail pharmaci go easiest
segment pharmaceut suppli chain amazon
enter howev also believ still tough
firm creat major disrupt within healthcar
space given insur dynam drive market
perspect new competitor need deal
larg power custom despit
market particip believ true end custom
pharmaceut space consum drug
rather insurer/employer/govern pay
health benefit consum accordingli expertis
need profit navig space preclud easi
opportun new entrant believ current
downward stock price move fear new disrupt
competit drug space creat opportun
investor acquir solid moati firm drug wholesal
pbm industri discount
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
access global suppli drug requir
viabl player within pbm pharma wholes
retail pharmaci space access everi legitim drug
requir due variabl demand health
insur product viabl pharma player need abl
access plethora drug
manufactur across world level access
achiev major drug market servic player
new entrant reach level
option clear major drug benefit provid
seller purchas pharmaceut
detail analysi competit dynam
pharmaceut space amazon podeti disrupt
pleas see report sell drug easier said done
moati pharma channel
perspect three key variabl
overlook market particip
stakehold analyz potenti new meaning
competit within pharmaceut market
true custom along chain busi
provid health benefit consum provid
health benefit make almost decis regard drug
pharmaci access busi also sourc suppli
drug partnership togeth b-to-b market
develop use drug health insur
base treat medic ailment consum demand
cash pay market estim less
prescript paid consum directli cash-
pay basi without insur dynam would take
mani consumer-bas compani built
core-compet get involv
pharmaceut space
price pharmaceut
drug price high-profil issu engulf
pharmaceut space percept new
entrant particular amazon instantli enter space
cut price drug product howev actual
price drug alreadi low given massiv amount
buy power pbm drug wholesal retail
pharmaci accumul new entrant would hold
minuscul amount purchas power compar
massiv joint sourc ventur
develop last hand year thu level
gener drug discount brand drug rebat new
entrant could command would pale comparison
major pharma supply-chain player make difficult
price competit
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
financi summari forecast
fiscal year end june
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
fiscal year end june
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
